This company has been acquired
SRRA Stock Overview
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Sierra Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.99 |
| 52 Week High | US$55.19 |
| 52 Week Low | US$14.91 |
| Beta | 0.015 |
| 11 Month Change | 0.20% |
| 3 Month Change | 43.77% |
| 1 Year Change | 179.42% |
| 33 Year Change | 143.49% |
| 5 Year Change | 18.51% |
| Change since IPO | -95.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| SRRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.06% | 4.3% | 1.6% |
| 1Y | 179.4% | 18.8% | 32.3% |
Return vs Industry: SRRA exceeded the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: SRRA exceeded the US Market which returned -19.1% over the past year.
Price Volatility
| SRRA volatility | |
|---|---|
| SRRA Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SRRA's share price has been volatile over the past 3 months.
Volatility Over Time: SRRA's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 109 | Stephen Dilly | www.sierraoncology.com |
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1.
Sierra Oncology, Inc. Fundamentals Summary
| SRRA fundamental statistics | |
|---|---|
| Market cap | US$1.34b |
| Earnings (TTM) | -US$102.67m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.1x
P/E RatioIs SRRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$59.88m |
| Gross Profit | -US$59.88m |
| Other Expenses | US$42.79m |
| Earnings | -US$102.67m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1.9% |
How did SRRA perform over the long term?
See historical performance and comparison